120 related articles for article (PubMed ID: 36972661)
1. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
[TBL] [Abstract][Full Text] [Related]
2. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
[TBL] [Abstract][Full Text] [Related]
3. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
Sokolova AO; Marshall CH; Lozano R; Gulati R; Ledet EM; De Sarkar N; Grivas P; Higano CS; Montgomery B; Nelson PS; Olmos D; Sokolov V; Schweizer MT; Yezefski TA; Yu EY; Paller CJ; Sartor O; Castro E; Antonarakis ES; Cheng HH
Prostate; 2021 Dec; 81(16):1382-1389. PubMed ID: 34516663
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
[TBL] [Abstract][Full Text] [Related]
6. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.
Castro E; Goh C; Olmos D; Saunders E; Leongamornlert D; Tymrakiewicz M; Mahmud N; Dadaev T; Govindasami K; Guy M; Sawyer E; Wilkinson R; Ardern-Jones A; Ellis S; Frost D; Peock S; Evans DG; Tischkowitz M; Cole T; Davidson R; Eccles D; Brewer C; Douglas F; Porteous ME; Donaldson A; Dorkins H; Izatt L; Cook J; Hodgson S; Kennedy MJ; Side LE; Eason J; Murray A; Antoniou AC; Easton DF; Kote-Jarai Z; Eeles R
J Clin Oncol; 2013 May; 31(14):1748-57. PubMed ID: 23569316
[TBL] [Abstract][Full Text] [Related]
7. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
[TBL] [Abstract][Full Text] [Related]
8. PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.
Castro E; Romero-Laorden N; Del Pozo A; Lozano R; Medina A; Puente J; Piulats JM; Lorente D; Saez MI; Morales-Barrera R; Gonzalez-Billalabeitia E; Cendón Y; García-Carbonero I; Borrega P; Mendez Vidal MJ; Montesa A; Nombela P; Fernández-Parra E; Gonzalez Del Alba A; Villa-Guzmán JC; Ibáñez K; Rodriguez-Vida A; Magraner-Pardo L; Perez-Valderrama B; Vallespín E; Gallardo E; Vazquez S; Pritchard CC; Lapunzina P; Olmos D
J Clin Oncol; 2019 Feb; 37(6):490-503. PubMed ID: 30625039
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer.
Park S; Lee E; Park S; Lee S; Nam SJ; Kim SW; Lee JE; Yu JH; Kim JY; Ahn JS; Im YH; Park WY; Park K; Park YH
Mol Cancer Res; 2020 Sep; 18(9):1315-1325. PubMed ID: 32554602
[TBL] [Abstract][Full Text] [Related]
10. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
[TBL] [Abstract][Full Text] [Related]
11. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
[TBL] [Abstract][Full Text] [Related]
12. Subgroups of familial and aggressive prostate cancer with considerable frequencies of BRCA2 mutations.
Maier C; Herkommer K; Luedeke M; Rinckleb A; Schrader M; Vogel W
Prostate; 2014 Oct; 74(14):1444-51. PubMed ID: 25111659
[TBL] [Abstract][Full Text] [Related]
13. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
[TBL] [Abstract][Full Text] [Related]
14. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
15. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers.
Gleicher S; Kauffman EC; Kotula L; Bratslavsky G; Vourganti S
Prostate; 2016 Sep; 76(13):1135-45. PubMed ID: 27225637
[TBL] [Abstract][Full Text] [Related]
16. High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer.
Willems-Jones A; Kavanagh L; Clouston D; Bolton D; ; Fox S; Thorne H
BJU Int; 2012 Dec; 110(11 Pt C):E1181-6. PubMed ID: 23035815
[TBL] [Abstract][Full Text] [Related]
17. Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
Nukaya T; Sumitomo M; Sugihara E; Takeda M; Nohara S; Tanishima S; Takenaka M; Zennami K; Takahara K; Shiroki R; Saya H
Cancer Med; 2023 Apr; 12(7):8154-8165. PubMed ID: 36645189
[TBL] [Abstract][Full Text] [Related]
18. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
Abdi B; Basset N; Perrot E; Benderra MA; Khalil A; Oudard S; Blanchet P; Brureau L; Coulet F; Cussenot O; Cancel-Tassin G
Prostate; 2022 Sep; 82(12):1196-1201. PubMed ID: 35652560
[TBL] [Abstract][Full Text] [Related]
19. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.
Edwards SM; Evans DG; Hope Q; Norman AR; Barbachano Y; Bullock S; Kote-Jarai Z; Meitz J; Falconer A; Osin P; Fisher C; Guy M; Jhavar SG; Hall AL; O'Brien LT; Gehr-Swain BN; Wilkinson RA; Forrest MS; Dearnaley DP; Ardern-Jones AT; Page EC; Easton DF; Eeles RA;
Br J Cancer; 2010 Sep; 103(6):918-24. PubMed ID: 20736950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
